JERUSALEM,
June 27, 2017
/PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)
(www.oramed.com), a clinical-stage
pharmaceutical company focused on the development of oral drug
delivery systems, announced today that the Japanese Intellectual
Property Office has publicized its intent to grant Oramed a patent
titled, "Methods and Compositions for Treating Diabetes" The patent
covers Oramed's invention of an oral insulin and glucagon-like
peptide-1 (GLP-1) analog combination composition (or
therapy).
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, Oramed's POD™
technology is based on over 30 years of research by scientists at
Jerusalem's Hadassah Medical
Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally
ingestible insulin capsule
(ORMD-0801). The Company completed
multiple Phase II clinical trials of ORMD-0801 under an
Investigational New Drug application with the U.S. Food and Drug
Administration. In addition, Oramed is developing an oral GLP-1
analog capsule (ORMD-0901).
For more information, the content of which is not part of
this press release, please visit
www.oramed.com
Forward-looking statements: This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
other federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates"
and similar expressions or variations of such words are intended to
identify forward-looking statements. For example, we are using
forward-looking statements when we discuss revolutionizing the
treatment of diabetes with our products. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Oramed
Pharmaceuticals
Estee
Yaari
+1-877-9-ORAMED
Email: estee@oramed.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oramed-granted-japanese-patent-for-combination-insulin-and-glp-1-analog-capsule-300480297.html
SOURCE Oramed Pharmaceuticals Inc.